From the Department of Neurological Surgery (A.A., N.A.S., P.G., W.M.-D., P.N., S.A.A., M.C.H., A.S., B.S.J., M.B.P.), Northwestern Memorial Hospital, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Department of Radiology (A.A., S.A.A., M.C.H., D.R.C., A.S., B.S.J., M.B.P.), Northwestern Memorial Hospital, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
AJNR Am J Neuroradiol. 2021 Oct;42(10):1827-1833. doi: 10.3174/ajnr.A7220. Epub 2021 Aug 12.
Experience with endoluminal flow diversion for the treatment of posterior circulation aneurysms is limited.
We sought to investigate factors associated with the safety and efficacy of this treatment by collecting disaggregated patient-level data from the literature.
PubMed, EMBASE, and Ovid were searched up through 2019 for articles reporting flow diversion of posterior circulation aneurysms.
Eighty-four studies reported disaggregated data for 301 separate posterior circulation aneurysms.
Patient, aneurysm, and treatment factors were collected for each patient. Outcomes included the occurrence of major complications, angiographic occlusion, and functional outcomes based on the mRS.
Significant differences in aneurysm and treatment characteristics were seen among different locations. Major complications occurred in 22%, angiographic occlusion was reported in 65% (11.3 months of mean follow-up), and good functional outcomes (mRS 0-2) were achieved in 67% (13.3 months of mean follow-up). Multivariate analysis identified age, number of flow diverters used, size, and prior treatment to be associated with outcome measures. Meta-analysis combining the current study with prior large nondisaggregated series of posterior circulation aneurysms treated with flow diversion found a pooled incidence of 20% ( = 712 patients) major complications and 75% ( = 581 patients) angiographic occlusions.
This study design is susceptible to publication bias. Use of antiplatelet therapy was not uniformly reported.
Endoluminal flow diversion is an important tool in the treatment of posterior circulation aneurysms. Patient age, aneurysm size, prior treatment, and the number of flow diverters used are important factors associated with complications and outcomes.
腔内血流转向术治疗后循环动脉瘤的经验有限。
我们通过从文献中收集离散的患者水平数据,旨在研究与该治疗相关的安全性和有效性的因素。
在 2019 年之前,通过 PubMed、EMBASE 和 Ovid 搜索了报道后循环动脉瘤血流转向术的文章。
84 项研究报告了 301 个单独的后循环动脉瘤的离散数据。
收集了每位患者的患者、动脉瘤和治疗因素。结果包括主要并发症的发生、血管造影闭塞和根据 mRS 评估的功能结果。
不同部位的动脉瘤和治疗特征存在显著差异。主要并发症发生率为 22%,血管造影闭塞率为 65%(平均随访 11.3 个月),功能良好(mRS 0-2)的比例为 67%(平均随访 13.3 个月)。多变量分析确定年龄、使用的血流转向器数量、大小和先前的治疗与结果测量相关。将当前研究与先前用血流转向术治疗后循环动脉瘤的大型非离散系列的荟萃分析相结合,发现主要并发症的合并发生率为 20%(=712 例),血管造影闭塞的发生率为 75%(=581 例)。
本研究设计易受发表偏倚的影响。抗血小板治疗的使用未得到统一报告。
腔内血流转向术是治疗后循环动脉瘤的重要工具。患者年龄、动脉瘤大小、既往治疗和使用的血流转向器数量是与并发症和结局相关的重要因素。